Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study-Reference-Cited by-同舟云学术

Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study

Published:2018-09-14 Issue:2 Volume:34 Page:364-369
ISSN:0815-9319
Container-title:Journal of Gastroenterology and Hepatology
language:en
Short-container-title:Journal of Gastroenterology and Hepatology

Author:

Atsukawa Masanori¹,Tsubota Akihito²,Toyoda Hidenori³^ORCID,Takaguchi Koichi⁴,Kondo Chisa¹,Okubo Tomomi⁵,Hiraoka Atsushi⁶,Michitaka Kojiro⁶,Fujioka Shinichi⁷,Uojima Haruki⁸^ORCID,Watanabe Tsunamasa⁹,Ikeda Hiroki⁹^ORCID,Asano Toru¹⁰,Ishikawa Toru¹¹,Matsumoto Yoshihiro²,Abe Hiroshi¹²,Kato Keizo¹²,Tsuji Kunihiko¹³,Ogawa Chikara¹⁴,Shimada Noritomo¹⁵,Iio Etsuko¹⁶,Mikami Shigeru¹⁷,Tanaka Yasuhito¹⁶,Kumada Takashi³,Iwakiri Katsuhiko¹

Affiliation:

1. Department of Internal Medicine, Division of Gastroenterology and Hepatology; Nippon Medical School; Tokyo Japan

2. The Core Research Facilities for Basic Science; The Jikei University School of Medicine; Tokyo Japan

3. Department of Gastroenterology; Ogaki Municipal Hospital; Ogaki Japan

4. Department of Hepatology; Kagawa Prefectural Central Hospital; Takamatsu Japan

5. Department of Gastroenterology; Nippon Medical School Chiba Hokusoh Hospital; Inzai Japan

6. Gastroenterology Center; Ehime Prefectural Central Hospital; Matsuyama Japan

7. Department of Gastroenterology; Okayama Saiseikai General Hospital; Okayama Japan

8. Department of Gastroenterology, Internal Medicine; Kitasato University School of Medicine; Sagamihara Japan

9. Department of Internal Medicine; St. Marianna University School of Medicine; Kawasaki Japan

10. Department of Internal Medicine, Division of Gastroenterology and Hepatology; Tokyo Metropolitan Bokutoh Hospital; Tokyo Japan

11. Department of Hepatology; Saiseikai Niigata Daini Hospital; Niigata Japan

12. Department of Internal Medicine, Division of Gastroenterology and Hepatology; Shinmatusdo Central General Hospital; Matsudo Japan

13. Center of Gastroenterology; Teine Keijinkai Hospital; Sapporo Japan

14. Department of Gastroenterology and Hepatology; Takamatsu Red Cross Hospital; Takamatsu Japan

15. Department of Internal Medicine, Division of Gastroenterology and Hepatology; Otakanomori Hospital; Kashiwa Japan

16. Department of Virology and Liver Unit; Nagoya City University; Nagoya Japan

17. Department of Internal Medicine, Division of Gastroenterology; Kikkoman General Hospital; Noda Japan

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jgh.14447/fullpdf

Reference49 articles.

1. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection;Kumada;Hepatology,2014

2. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection;Afdhal;N. Engl. J. Med.,2014

3. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis;Kowdley;N. Engl. J. Med,2014

4. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection;Afdhal;N. Engl. J. Med.,2014

5. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial;Mizokami;Lancet Infect. Dis,2015

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis;Frontiers in Public Health;2023-09-29

2. A novel formula used for predicting hepatocellular carcinoma after the achievement of sustained virologic response by direct-acting antivirals in patients with chronic hepatitis C;PLOS ONE;2023-09-21

3. Pharmacokinetics, Tolerability, and Safety of Glecaprevir/Pibrentasvir Co‐formulated Bilayer Tablet Following Repeated Administration in Healthy Chinese Adults;Clinical Pharmacology in Drug Development;2023-09-04

4. Current elimination status of hepatitis C virus‐infected maintenance hemodialysis patients in Iwate Prefecture, Japan;Therapeutic Apheresis and Dialysis;2023-05

5. A Systematic Review of Direct-Acting Antivirals for Hepatitis C in Advanced CKD;Kidney International Reports;2023-02